AGENSYS Cancer Peptide Patent US12612429B2 Granted April 2026
Summary
USPTO granted patent US12612429B2 to AGENSYS, INC. on April 28, 2026 for derivatives of dolaproine-dolaisoleuine peptide analogs and pharmaceutical compositions for treating cancer. The patent names Brian Alan Mendelsohn, Julien Dugal-Tessier, and Stuart Daniel Barnscher as inventors, with 16 claims allowed. The application was filed on March 18, 2022 under application number 17698353.
“Provided are peptide analogs, pharmaceutical compositions comprising such compounds, and methods of treating cancer with such compounds.”
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
What changed
USPTO granted patent US12612429B2 to AGENSYS, INC. for peptide analogs and pharmaceutical compositions useful for treating cancer, with the patent issuing on April 28, 2026. The 16-claim patent covers dolaproine-dolaisoleuine peptide derivatives and methods of treatment using such compounds.
This patent grant provides AGENSYS with exclusive intellectual property rights to the specified peptide compounds and their therapeutic applications. Competitors developing similar dolaproine-dolaisoleuine peptide analogs for cancer treatment should review their products for potential infringement of the granted claims.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Derivatives of dolaproine-dolaisoleuine peptides
Grant US12612429B2 Kind: B2 Apr 28, 2026
Assignee
AGENSYS, INC.
Inventors
Brian Alan Mendelsohn, Julien Dugal-Tessier, Stuart Daniel Barnscher
Abstract
Provided are peptide analogs, pharmaceutical compositions comprising such compounds, and methods of treating cancer with such compounds.
CPC Classifications
C07K 5/0205 C07K 7/02 A61K 38/07 A61K 38/00 A61K 38/03 A61K 38/08 A61P 35/00
Filing Date
2022-03-18
Application No.
17698353
Claims
16
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.